An open-label study of ziprasidone in pediatric patients with bipolar disorder: Safety, tolerability, efficacy, and functional outcomes

被引：0
|
作者：
DelBello, Melissa
Versavel, Mark
Ice, Kathleen
Keller, David
Stewart, Michelle
Miceli, Jeffrey
机构：
[1] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA
[2] Pfizer Inc, Groton, CT 06340 USA
来源：
BIPOLAR DISORDERS | 2006年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
63
引用
收藏
页码：27 / 27
页数：1
相关论文
共 50 条
  • [1] CHQ and CGAS in an open-label study of ziprasidone in pediatric patients with bipolar disorder, schizophrenia, or schizoaffective disorder
    DelBello, Melissa
    Stewart, Michelle
    Versavel, Mark
    Keller, David
    Miceli, Jeffrey
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2006, 16 (06) : 662 - 662
  • [2] An open-label study of ziprasidone in children with bipolar disorder
    Biederman, J
    Harpold, T
    Hammerness, P
    Mick, E
    Dougherty, M
    Aleardi, M
    Randall, E
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 106S - 107S
  • [3] Safety and Efficacy of Ziprasidone in Pediatric Bipolar Disorder
    DelBello, Melissa
    Findling, Robert L.
    Wang, Paul
    Gundapaneni, Balarama
    Versavel, Mark
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2008, 18 (06) : 632 - 632
  • [4] Safety and efficacy of ziprasidone in pediatric bipolar disorder
    DelBello, Melissa P.
    Findling, Robert L.
    Wang, Paul P.
    Gundapaneni, Balarama
    Versavel, Mark
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 283S - 283S
  • [5] The Efficacy and Safety of Switching to Ziprasidone from Olanzapine in Patients with Bipolar I Disorder: An 8-Week, Multicenter, Open-Label Study
    Lee, Hwang-Bin
    Yoon, Bo-Hyun
    Kwon, Young-Joon
    Woo, Young Sup
    Lee, Jung-Goo
    Kim, Moon-Doo
    Bahk, Won-Myong
    CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 743 - 753
  • [6] Safety and efficacy of ziprasidone in pediatric bipolar disorder
    Findling, R.
    DelBello, M.
    Wang, P.
    Gundapaneni, B.
    Versavel, M.
    Karayal, O.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S682 - S683
  • [7] The Efficacy and Safety of Switching to Ziprasidone from Olanzapine in Patients with Bipolar I Disorder: An 8-Week, Multicenter, Open-Label Study
    Hwang-Bin Lee
    Bo-Hyun Yoon
    Young-Joon Kwon
    Young Sup Woo
    Jung-Goo Lee
    Moon-Doo Kim
    Won-Myong Bahk
    Clinical Drug Investigation, 2013, 33 : 743 - 753
  • [8] Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder
    Ketter, T. A.
    Sachs, G. S.
    Lu, K.
    Ruth, A.
    Laszlovszky, I.
    Nagy, K.
    Starace, A.
    Durgam, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S377 - S377
  • [9] Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder
    Ketter, T. A.
    Sachs, G.
    Lu, K.
    Laszlovszky, I.
    Nagy, K.
    Starace, A.
    Durgam, S.
    BIPOLAR DISORDERS, 2013, 15 : 134 - 134
  • [10] Ziprasidone in the treatment of children and adolescents with bipolar mania or schizophrenia: An open-label, dose-ranging safety and tolerability study
    DelBello, M
    Ice, K
    Fisher, DO
    Versavel, M
    Miceli, JJ
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (06) : 861 - 861
12345